ABEO
- Abeona Therapeutics Inc.
()
Overview
Company Summary
Abeona Therapeutics Inc. (ABEO) is a biopharmaceutical company that primarily operates in the field of gene and cell therapy. The company focuses on the development and commercialization of genetic treatments for rare genetic diseases with high unmet medical needs.
Abeona Therapeutics aims to create innovative therapies that use genes and cells to address the underlying causes of diseases. Their approach involves delivering corrected genes or healthy cells into affected tissues to restore normal function or provide therapeutic benefits. This is particularly valuable for treating rare diseases caused by genetic mutations.
The company's pipeline of products includes experimental gene and cell therapies for various rare diseases, such as Sanfilippo syndrome, Recessive Dystrophic Epidermolysis Bullosa, and Batten disease. They have designed gene therapies to deliver functioning genes directly into patients' cells, bypassing the faulty ones.
Abeona Therapeutics also collaborates with academic institutions, research organizations, and biotechnology companies to leverage their expertise and resources in advancing their scientific and clinical programs. The company aims to develop safe and effective treatments, obtain regulatory approvals, and ultimately make these therapies available to patients globally.
In addition to its scientific pursuits, Abeona Therapeutics ensures to follow ethical and regulatory standards throughout its research, clinical trials, and commercialization activities. They prioritize patient safety, product quality, and adherence to applicable laws and regulations.
Overall, Abeona Therapeutics is dedicated to pushing the boundaries of medical science and utilizing gene and cell therapies to combat rare genetic diseases and improve the lives of patients affected by these conditions.